Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Phase 4

• Conditions: Health Condition 1: null- HIV positive participants

• Registration Number: CTRI/2017/09/009938
• Lead Sponsor: ational Institute Of Allergy and Infectious DiseasesNIAIDNIH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-09-02
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

NOTE: All potential participants with prior RAL exposure will be assigned to Cohort D.

3.Current receipt of a PI-based regimen with no regimen change for a minimum of 24 weeks prior to screening.

NOTE A: Within the 30 days prior to collection of the confirmatory VF sample (see 4.1.4), alteration in dose, dose frequency, or any within-class substitution(s) for intolerance is permitted, as are drug interruptions for fewer than 7 cumulative days.

NOTE B: There can be no changes and no drug interruptions within the 3 days immediately prior to the collection of the confirmatory VF sample

Exclusion Criteria

Contraindication to the proposed Step 2 ARV regimen as determined by the site investigator.

Indication for discontinuation of RAL, ETR, or DRV.

Study & Design

• Study Type: Interventional
• Study Design: Not specified